Ares Financial Consulting
UTHR icon

Ares Financial Consulting’s United Therapeutics UTHR Stock Holding History

Ares Financial Consulting’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.63K Sell
3
-4
-57% -$2.07K ﹤0.01% 909
2026
Q2 		$3.79K Buy
7
+4
+133% +$2.25K ﹤0.01% 780
2026
Q1 		$1.71K Hold
3
– – ﹤0.01% 871
2025
Q4 		$1.46K Buy
+3
New +$1.4K ﹤0.01% 713

Other funds holding UTHR

Amundi
Amundi Paris, France $496B AUM 35.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
AssetMark Inc
AssetMark Inc Concord, California $59.5B AUM 15.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $106B AUM 32.76% 1-Year Est. Return
Citigroup
Citigroup New York $308B AUM 40.94% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Fifth Third Bancorp
Fifth Third Bancorp Cincinnati, Ohio $61.2B AUM 25.19% 1-Year Est. Return

Ares Financial Consulting's UTHR Position: Q3 2026 in Review

Ares Financial Consulting reduced its United Therapeutics (UTHR) stake by 57% in Q3 2026, selling an estimated $2.07K and leaving 3 shares worth $1.63K. The position accounts for ﹤0.01% of the portfolio, ranked #909.

Ares Financial Consulting first reported a position in UTHR in Q4 2025 and has held it in 4 quarters since. The position peaked at $3.79K in Q2 2026. 390 funds tracked by Wall St. Rank hold UTHR as of Q3 2026.

  • Ares Financial Consulting held 3 shares of United Therapeutics worth $1.63K as of Q3 2026.
  • Ares Financial Consulting sold 4 United Therapeutics shares in Q3 2026, an estimated $2.07K.
  • United Therapeutics made up ﹤0.01% of Ares Financial Consulting's portfolio in Q3 2026, its #909 holding.
  • Ares Financial Consulting first reported a position in United Therapeutics in Q4 2025 and has held it in 4 quarters since.
  • Ares Financial Consulting's United Therapeutics position peaked at $3.79K in Q2 2026.
  • 390 funds tracked by Wall St. Rank held United Therapeutics as of Q3 2026.

Based on Ares Financial Consulting's 13F filing for Q3 2026, filed 19 Oct 2026.